AU2001259029B2 - Il-17 receptor like molecules and uses thereof - Google Patents

Il-17 receptor like molecules and uses thereof Download PDF

Info

Publication number
AU2001259029B2
AU2001259029B2 AU2001259029A AU2001259029A AU2001259029B2 AU 2001259029 B2 AU2001259029 B2 AU 2001259029B2 AU 2001259029 A AU2001259029 A AU 2001259029A AU 2001259029 A AU2001259029 A AU 2001259029A AU 2001259029 B2 AU2001259029 B2 AU 2001259029B2
Authority
AU
Australia
Prior art keywords
polypeptide
receptor
seq
nucleic acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001259029A
Other languages
English (en)
Other versions
AU2001259029A1 (en
Inventor
Gary S. Elliot
Shuqian Jing
Eugene Medlock
Hung Q. Nguyen
Scott M. Silbiger
Richard Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2001259029A1 publication Critical patent/AU2001259029A1/en
Application granted granted Critical
Publication of AU2001259029B2 publication Critical patent/AU2001259029B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001259029A 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof Ceased AU2001259029B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US18992300P 2000-03-16 2000-03-16
US60/189,923 2000-03-16
US20420800P 2000-05-12 2000-05-12
US60/204,208 2000-05-12
US72323200A 2000-11-27 2000-11-27
US09/723,232 2000-11-27
US26615901P 2001-02-02 2001-02-02
US60/266,159 2001-02-02
PCT/US2001/008688 WO2001068705A2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Publications (2)

Publication Number Publication Date
AU2001259029A1 AU2001259029A1 (en) 2001-12-06
AU2001259029B2 true AU2001259029B2 (en) 2006-01-05

Family

ID=27497823

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001259029A Ceased AU2001259029B2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof
AU5902901A Pending AU5902901A (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5902901A Pending AU5902901A (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Country Status (8)

Country Link
EP (1) EP1265924A2 (enExample)
JP (1) JP2003527117A (enExample)
AR (1) AR030554A1 (enExample)
AU (2) AU2001259029B2 (enExample)
CA (1) CA2401273A1 (enExample)
MX (1) MXPA02009024A (enExample)
TW (1) TWI322154B (enExample)
WO (1) WO2001068705A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202616B2 (en) * 2000-06-22 2011-08-18 Amgen Inc. IL-17 Like Molecules and Uses Thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1897944B1 (en) * 1999-12-23 2011-08-10 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002058717A2 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
AU2003263751A1 (en) * 2002-08-05 2004-02-23 Eli Lilly And Company Novel proteins and their uses
EP1562587A4 (en) * 2002-09-11 2006-07-19 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2081585A2 (en) * 2006-10-13 2009-07-29 The Regents of the University of California Cancer treatment
WO2009069355A1 (ja) * 2007-11-28 2009-06-04 Riken Ｉｌ－１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
GB0905972D0 (en) * 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
HRP20180340T1 (hr) * 2010-03-30 2018-03-23 Janssen Biotech, Inc. Humanizirana il-25 protutijela
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69233441T2 (de) 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
WO1994028122A1 (en) 1993-05-26 1994-12-08 Ontario Cancer Institute Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1996020206A1 (en) 1994-12-23 1996-07-04 Uab Research Foundation Secreted human fas antigen
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
CA2244363C (en) 1996-02-28 2006-11-14 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
DE69841140D1 (de) * 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
JP2003502006A (ja) * 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
AR022237A1 (es) * 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP1165788A2 (en) * 1999-04-05 2002-01-02 Incyte Pharmaceuticals, Inc. Molecules of the immune system
AU2001236638A1 (en) * 2000-02-04 2001-08-14 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
MXPA02007674A (es) * 2000-02-08 2002-12-13 Amgen Inc Moleculas similares a interlucina-17 y uso de las mismas.
US9100155B2 (en) 2010-05-03 2015-08-04 Qualcomm Incorporated Method and apparatus for control and data multiplexing in wireless communication
JP6160461B2 (ja) 2013-11-29 2017-07-12 富士通株式会社 尤度重み付け回路

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202616B2 (en) * 2000-06-22 2011-08-18 Amgen Inc. IL-17 Like Molecules and Uses Thereof

Also Published As

Publication number Publication date
CA2401273A1 (en) 2001-09-20
JP2003527117A (ja) 2003-09-16
WO2001068705A2 (en) 2001-09-20
EP1265924A2 (en) 2002-12-18
WO2001068705A3 (en) 2002-07-18
AU5902901A (en) 2001-09-24
TWI322154B (en) 2010-03-21
MXPA02009024A (es) 2003-02-12
AR030554A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
US7943738B2 (en) IL-17 receptor like molecules and uses thereof
AU2001272968C1 (en) Il-17 molecules and uses thereof
AU2001259029B2 (en) Il-17 receptor like molecules and uses thereof
AU2001272968A1 (en) Il-17 molecules and uses thereof
US20140037635A1 (en) Methods of treatment using il-17e antagonists
US20040048338A1 (en) IL-17 receptor like molecules and uses thereof
AU2001259029A1 (en) Il-17 receptor like molecules and uses thereof
US20030166069A1 (en) Interleukin-1 receptor antagonist-like molecules and uses thereof
WO2001042304A1 (en) Interleukin-1 receptor antagonist-related molecules and uses thereof
US20040208872A1 (en) Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof
AU2007202616B2 (en) IL-17 Like Molecules and Uses Thereof
US20050123512A1 (en) Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof
WO2001042305A1 (en) Interleukin-1 receptor antagonist-like molecules and uses thereof
AU1945001A (en) Interleukin-1 receptor antagonist-related molecules and uses thereof
US20030099980A1 (en) IL-17 receptor like molecules and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired